FIELD: medicine, pharmacology.
SUBSTANCE: compound formula I is described, including the pharmaceutically acceptable salts, 
, where: Z presents 
; Q is taken from the group that consists of: 
-W - presents 
, and the pharmaceutical composition, application of compound formula (I) for preparation of antiviral medicine.
EFFECT: proposed compounds can be helpful in treatment of HIV and AIDS.
70 cl, 2 tbl, 129 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | 2013 |
|
RU2660429C2 |
| MONOMER DERIVATIVES OF GLYCOPEPTIDE ANTIBIOTIC | 2005 |
|
RU2424248C2 |
| AZAINDOLEOXOACETIC DERIVATIVES OF PIPERAZINE AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2002 |
|
RU2303038C2 |
| NEMATOCIDAL SULPHONAMIDES | 2010 |
|
RU2531317C2 |
| DERIVATIVES OF PYRAZIOLE WITH CONDENSED CYCLE | 2002 |
|
RU2318822C2 |
| BRIDGED N-CYCLYC SULPHONAMIDO-INHIBITORS OF GAMMA-SECRETASE | 2006 |
|
RU2422443C2 |
| COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | 2019 |
|
RU2795108C2 |
| ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | 2015 |
|
RU2707749C2 |
| HETEROCYCLIC COMPOUNDS, EFFECTIVE FOR KINASE INHIBITION | 2011 |
|
RU2640862C2 |
| INHIBITION OF CREB-BINDING PROTEIN (CBP) | 2019 |
|
RU2803290C2 |
